Literature DB >> 17475587

Liver transplantation for combined hepatocellular cholangiocarcinoma.

Albert Chi-Yan Chan1, Chung Mau Lo, Irene Oi-Lin Ng, Sheung Tat Fan.   

Abstract

Combined hepatocellular cholangiocarcinoma (cHCC-CC) is an uncommon histological variant of primary liver cancer. This combined type of tumour lesion follows an aggressive clinical course with an unfavourable prognosis. Although the role of orthotopic liver transplantation in the management for hepatocellular carcinoma is well defined, to date, there has been no report on its treatment value for cHCC-CC. We report our experience of orthotopic liver transplantation in three patients with cHCC-CC. One patient succumbed to distant metastases 16.5 months after liver transplantation whereas the other two patients continued to survive 35 and 25 months after transplantation, respectively.

Entities:  

Mesh:

Year:  2007        PMID: 17475587     DOI: 10.1016/S1015-9584(09)60149-4

Source DB:  PubMed          Journal:  Asian J Surg        ISSN: 1015-9584            Impact factor:   2.767


  17 in total

1.  A case of combined hepatocellular-cholangiocarcinoma with favorable response to systemic chemotherapy.

Authors:  Gun Min Kim; Hei-Cheul Jeung; Dokyung Kim; Joo Hoon Kim; Sang Hyun Yoon; Eun Suk Jung; Sang Joon Shin
Journal:  Cancer Res Treat       Date:  2010-12-31       Impact factor: 4.679

Review 2.  Impact of incidental/misdiagnosed intrahepatic cholangiocarcinoma and combined hepatocellular cholangiocarcinoma on the outcomes of liver transplantation: an institutional case series and literature review.

Authors:  Rahul Gupta; Junichi Togashi; Nobuhisa Akamatsu; Yoshihiro Sakamoto; Norihiro Kokudo
Journal:  Surg Today       Date:  2017-01-25       Impact factor: 2.549

Review 3.  Liver Transplantation for Cholangiocarcinoma: Insights into the Prognosis and the Evolving Indications.

Authors:  Guergana G Panayotova; Flavio Paterno; James V Guarrera; Keri E Lunsford
Journal:  Curr Oncol Rep       Date:  2020-04-16       Impact factor: 5.075

Review 4.  Liver transplantation for hepatobiliary malignancies: a new era of "Transplant Oncology" has begun.

Authors:  Taizo Hibi; Osamu Itano; Masahiro Shinoda; Yuko Kitagawa
Journal:  Surg Today       Date:  2016-04-29       Impact factor: 2.549

5.  Living donor liver transplantation for hepatocellular carcinoma at the University of Tokyo Hospital.

Authors:  Junichi Togashi; Nobuhisa Akamastu; Norihiro Kokudo
Journal:  Hepatobiliary Surg Nutr       Date:  2016-10       Impact factor: 7.293

Review 6.  Combined hepatocellular cholangiocarcinoma: Controversies to be addressed.

Authors:  An-Qiang Wang; Yong-Chang Zheng; Juan Du; Cheng-Pei Zhu; Han-Chun Huang; Shan-Shan Wang; Liang-Cai Wu; Xue-Shuai Wan; Hao-Hai Zhang; Ruo-Yu Miao; Xin-Ting Sang; Hai-Tao Zhao
Journal:  World J Gastroenterol       Date:  2016-05-14       Impact factor: 5.742

7.  Long-term outcome of patients undergoing liver transplantation for mixed hepatocellular carcinoma and cholangiocarcinoma: an analysis of the UNOS database.

Authors:  Valery Vilchez; Malay B Shah; Michael F Daily; Luis Pena; Ching-Wei D Tzeng; Daniel Davenport; Peter J Hosein; Roberto Gedaly; Erin Maynard
Journal:  HPB (Oxford)       Date:  2016-01-07       Impact factor: 3.647

8.  Hepatocholangiocarcinoma/intrahepatic cholangiocarcinoma: are they contraindication or indication for liver transplantation? A propensity score-matched analysis.

Authors:  Ka Wing Ma; Kenneth Siu Ho Chok; Wong Hoi She; Tan To Cheung; Albert Chi Yan Chan; Wing Chiu Dai; James Yan Yue Fung; Chung Mau Lo
Journal:  Hepatol Int       Date:  2018-02-15       Impact factor: 6.047

Review 9.  Current status of the organ replacement approach for malignancies and an overture for organ bioengineering and regenerative medicine.

Authors:  Taizo Hibi; Masahiro Shinoda; Osamu Itano; Yuko Kitagawa
Journal:  Organogenesis       Date:  2014-05-16       Impact factor: 2.500

10.  Outcome of combined hepatocellular and cholangiocarcinoma of the liver.

Authors:  Jue Wang; Fenwei Wang; Anne Kessinger
Journal:  J Oncol       Date:  2010-09-02       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.